| Literature DB >> 28958334 |
Carlo Patrono1, Joao Morais2, Colin Baigent3, Jean-Philippe Collet4, Desmond Fitzgerald5, Sigrun Halvorsen6, Bianca Rocca7, Agneta Siegbahn8, Robert F Storey9, Gemma Vilahur10.
Abstract
Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.Entities:
Keywords: aspirin; cangrelor; clopidogrel; prasugrel; ticagrelor; vorapaxar
Mesh:
Substances:
Year: 2017 PMID: 28958334 DOI: 10.1016/j.jacc.2017.08.037
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094